Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in moderate hidradenitis suppurativa
2016-000859-27Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of apremilast in hidradenitis suppurativa (HS), sponsored by Erasmus MC. Primary endpoint: Inflammatory cytokine expression in HS lesional skin at week 16. Started Jun 2016; status: active.
02
Drugs
apremilast
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2016-000859-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000859-27.